Summary & Overview
HCPCS J1327: Injection, eptifibatide 5 mg
HCPCS Level II code J1327 identifies a 5 mg injection of eptifibatide, a parenteral antiplatelet agent used in acute cardiovascular care. This code matters nationally because eptifibatide is used in high-acuity settings—such as during percutaneous coronary intervention and other acute coronary syndromes—where medication billing, dosing units, and site-of-service considerations affect cost and reimbursement. Accurate coding ensures appropriate payment and supports clinical inventory and utilization management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding purpose and clinical context, payer coverage considerations, and common billing elements associated with J1327. The publication provides benchmark insights, notes on site-of-service implications, and a summary of what to expect in claims processing for this injectable medication. Where input data is incomplete, the text indicates the absence of specific fields. The goal is to give revenue cycle, clinical, and compliance stakeholders a clear, national-level briefing on HCPCS Level II code J1327 and its role in billing for eptifibatide administration.
Billing Code Overview
HCPCS Level II code J1327 represents an injection of eptifibatide, 5 mg. This code is used to bill for administration of the antiplatelet agent eptifibatide in a single 5 mg unit.
Service Type: Medication administration (intravenous antiplatelet therapy)
Typical Site of Service: Hospital inpatient, hospital outpatient, and other acute care settings where intravenous antiplatelet therapy is provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old male presenting to the emergency department with acute chest pain, ST-segment changes on ECG, and elevated cardiac biomarkers consistent with an acute coronary syndrome (non–ST-elevation myocardial infarction or high-risk unstable angina). After initial evaluation and antithrombotic risk assessment, the interventional cardiology team prepares for percutaneous coronary intervention (PCI). During vascular access and coronary angiography, thrombotic burden or high-risk lesion morphology is identified, and adjunctive intravenous platelet glycoprotein IIb/IIIa inhibitor therapy is indicated. The medication administered is eptifibatide, billed using J1327 for each 5 mg vial used.
In the clinical workflow, the emergency or cardiology team documents the indication (e.g., NSTEMI with high thrombus burden), orders weight- or creatinine-adjusted dosing, and the pharmacy prepares the required number of J1327 vials. Nursing administers a bolus followed by infusion per protocol in the cardiac catheterization laboratory or coronary care unit. The medication administration is recorded in the medication administration record and linked to the procedure note, and billing uses J1327 units corresponding to the number of 5 mg vials dispensed and administered. Typical sites of service include the cardiac catheterization laboratory, emergency department, and inpatient coronary care unit.
Coding Specifications
| Modifier | Description | When to Use |
|---|